Momenta Pharmaceuticals, Inc.
MNTA
MNTA was delisted on the 30th of September, 2020.
146 hedge funds and large institutions have $638M invested in Momenta Pharmaceuticals, Inc. in 2016 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 64 increasing their positions, 35 reducing their positions, and 23 closing their positions.
810% more call options, than puts
Call options by funds: $2.69M | Put options by funds: $296K
83% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 35
16% more capital invested
Capital invested by funds: $548M → $638M (+$89.5M)
4% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 23
1% less funds holding
Funds holding: 148 → 146 (-2)
2.11% less ownership
Funds ownership: 85.45% → 83.33% (-2.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
+$24.9M |
| 2 |
NRC
North Run Capital
Boston,
Massachusetts
|
+$7.43M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$6.54M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.74M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$2.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$6.85M |
| 2 |
State Street
Boston,
Massachusetts
|
-$4.78M |
| 3 |
SAM
Senzar Asset Management
New York
|
-$4.04M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$3.95M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.23M |
MNTA Hedge Fund Activity: Q2 2016 in Review
146 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Momenta Pharmaceuticals, Inc. (MNTA) for Q2 2016, worth a combined $638M — up 16% from $548M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of MNTA and 22 opened new positions — a net loss of 1 holder — while 35 trimmed existing stakes and 64 added.
The largest buyer was Fiera Capital (Canada), opening a new position worth an estimated $24.9M. The largest seller was Renaissance Technologies, cutting an estimated $6.85M.
- 146 institutional investors held Momenta Pharmaceuticals, Inc. (MNTA) as of Q2 2016, down from 148 in Q1 2016.
- Funds reported $638M of Momenta Pharmaceuticals, Inc. stock for Q2 2016, up 16% quarter-over-quarter.
- 22 funds opened new Momenta Pharmaceuticals, Inc. positions in Q2 2016 and 23 closed out, a net change of -1 holder.
- The largest Momenta Pharmaceuticals, Inc. buyer in Q2 2016 was Fiera Capital (Canada), an estimated $24.9M added.
- The largest Momenta Pharmaceuticals, Inc. seller in Q2 2016 was Renaissance Technologies, an estimated $6.85M sold.
Based on aggregated 13F filings for Q2 2016.